Medindia

X

Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Clostridium Difficile Infection

Friday, February 5, 2010 Research News J E 4
Advertisement
Data Confirms Fidaxomicin Provided Statistically Significant Difference in Recurrence Rates and Global Cure Rates vs. Vancocin(R)

Contacts

Optimer Pharmaceuticals, Inc.

Christina Donaghy, Corporate Communications Manager

John D. Prunty, Chief Financial Officer & VP Finance

858-909-0736

Porter Novelli Life Sciences

Jason I. Spark, Vice President

619-849-6005

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Accuray Announces Results for Second Quarter Fisca...
S
BioMarin Announces 2010 Guidance